USP8 and neoplasm: Taken together, these results reveal a molecular mechanism and potential strategy of combination therapy of USP8 inhibitor plus anti-PD-1/PD-L1 antibody to enhance the efficacy of anti-tumor therapy largely through reprograming an inflamed TME.